TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 245-251

  Bories, Phuong Nhi ^a   Younes, Patrick ^a   Zerbib, Marc ^a   Denjean, Lydie ^a   Popovici, Theodora ^a   Cynober, Luc ^a,b   Delongchamps, Nicolas Barry ^a  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; EXON; FINE NEEDLE ASPIRATION BIOPSY; FUSION GENE; GENETIC VARIABILITY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINALYSIS; URINE;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEEDLES; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84872029478     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.192260     Document Type: Article

References (28)

1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012;61:1079-92.
2. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 2010;58:851-64.
3. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007;99:1484-9.
4. Arcangeli CG, Humphrey PA, Smith DS, Harmon TJ, Shepherd DL, Keetch DW, Catalona WJ. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 1998;51:558-65.
5. Jansen FH, van Schaik RHN, Kurstjens J, Horninger W, Klocker H, Bektic J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7.
6. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
8. Sunami E, Shinozaki M, Higano CS, Wollman R, Dorff TB, Tucker SJ, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 2009;55:559-67.
9. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.
10. Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 2011;71:700-10.
11. Vener T, Derecho C, Baden J, Wang H, Rajpurohit Y, Skelton J, et al. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin Chem 2008;54:874-82.
12. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43-9.
13. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol [Epub ahead of print 2011 May 19].
14. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-51.
15. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 2006;45:717-9.
16. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007;26:2667-73.
17. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009;15:4706-11.
18. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95.
19. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.
20. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.
21. Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, et al. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem 2008;54:2007-17.
22. Rostad K, Hellwinkel OJ, Haukaas SA, Halvorsen OJ, Øyan AM, Haese A, et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. APMIS 2009;117:575-82.
23. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 2011;3:94ra72.
24. Nguyen PN, Violette P, Chan S, Tanguay S, Kassouf W, Aprikian A, Chen JZ. A panel of TMPRSS2:ERG fusion transcript markers for urine-based prostate cancer detection with high specificity and sensitivity. Eur Urol 2011;59:407-14.
25. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-3.
26. D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a Gleason score
27. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine: a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-6.
28. Wittor H, Leying H, Hochlaus A, van Miltenburg R. Real-time quantification of BCR-ABL mRNA using the LightCycler-t(9;22) quantification kit. http://www.roche-applied-science.com/PROD-INF/BIOCHEMI/no2-00/PDF/p8-12.pdf.